Puentes LN - Search Results

1

Synthesis and evaluation of an AZD2461 [¹⁸F]PET probe in non-human primates reveals the PARP-1 inhibitor to be non-blood-brain barrier penetrant.

Reilly SW, Puentes LN, Schmitz A, Hsieh CJ, Weng CC, Hou C, Li S, Kuo YM, Padakanti P, Lee H, Riad AA, Makvandi M, Mach RH. Reilly SW, et al. Among authors: puentes ln. Bioorg Chem. 2019 Mar;83:242-249. doi: 10.1016/j.bioorg.2018.10.015. Epub 2018 Oct 17. Bioorg Chem. 2019. PMID: 30390553 Free PMC article.

2

Examination of Diazaspiro Cores as Piperazine Bioisosteres in the Olaparib Framework Shows Reduced DNA Damage and Cytotoxicity.

Reilly SW, Puentes LN, Wilson K, Hsieh CJ, Weng CC, Makvandi M, Mach RH. Reilly SW, et al. Among authors: puentes ln. J Med Chem. 2018 Jun 28;61(12):5367-5379. doi: 10.1021/acs.jmedchem.8b00576. Epub 2018 Jun 14. J Med Chem. 2018. PMID: 29856625 Free PMC article.

3

Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models.

Makvandi M, Lee H, Puentes LN, Reilly SW, Rathi KS, Weng CC, Chan HS, Hou C, Raman P, Martinez D, Xu K, Carlin SD, Greenberg RA, Pawel BR, Mach RH, Maris JM, Pryma DA. Makvandi M, et al. Among authors: puentes ln. Mol Cancer Ther. 2019 Jul;18(7):1195-1204. doi: 10.1158/1535-7163.MCT-18-0837. Epub 2019 May 9. Mol Cancer Ther. 2019. PMID: 31072830 Free PMC article.

4

Molecular Imaging: PARP-1 and Beyond.

Puentes LN, Makvandi M, Mach RH. Puentes LN, et al. J Nucl Med. 2021 Jun 1;62(6):765-770. doi: 10.2967/jnumed.120.243287. Epub 2021 Feb 12. J Nucl Med. 2021. PMID: 33579802 Free article. Review.

5

Evaluation of a Low-Toxicity PARP Inhibitor as a Neuroprotective Agent for Parkinson's Disease.

Puentes LN, Lengyel-Zhand Z, Reilly SW, Mach RH. Puentes LN, et al. Mol Neurobiol. 2021 Aug;58(8):3641-3652. doi: 10.1007/s12035-021-02371-4. Epub 2021 Mar 31. Mol Neurobiol. 2021. PMID: 33788167

6

Altering Nitrogen Heterocycles of AZD2461 Affords High Affinity Poly(ADP-ribose) Polymerase-1 Inhibitors with Decreased P-Glycoprotein Interactions.

Reilly SW, Puentes LN, Hsieh CJ, Makvandi M, Mach RH. Reilly SW, et al. Among authors: puentes ln. ACS Omega. 2018 Aug 31;3(8):9997-10001. doi: 10.1021/acsomega.8b00896. Epub 2018 Aug 28. ACS Omega. 2018. PMID: 30198004 Free PMC article.

7

PARkinson's: From cellular mechanisms to potential therapeutics.

Lengyel-Zhand Z, Puentes LN, Mach RH. Lengyel-Zhand Z, et al. Among authors: puentes ln. Pharmacol Ther. 2022 Feb;230:107968. doi: 10.1016/j.pharmthera.2021.107968. Epub 2021 Aug 12. Pharmacol Ther. 2022. PMID: 34391789 Free PMC article. Review.

8

ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells.

Verma P, Zhou Y, Cao Z, Deraska PV, Deb M, Arai E, Li W, Shao Y, Puentes L, Li Y, Patankar S, Mach RH, Faryabi RB, Shi J, Greenberg RA. Verma P, et al. Nat Cell Biol. 2021 Feb;23(2):160-171. doi: 10.1038/s41556-020-00624-3. Epub 2021 Jan 18. Nat Cell Biol. 2021. PMID: 33462394 Free PMC article.

9

Poly (ADP-ribose) Interacts With Phosphorylated α-Synuclein in Post Mortem PD Samples.

Puentes LN, Lengyel-Zhand Z, Lee JY, Hsieh CJ, Schneider ME Jr, Edwards KJ, Luk KC, Lee VM, Trojanowski JQ, Mach RH. Puentes LN, et al. Front Aging Neurosci. 2021 Jun 18;13:704041. doi: 10.3389/fnagi.2021.704041. eCollection 2021. Front Aging Neurosci. 2021. PMID: 34220490 Free PMC article.

10

TMEM97 and PGRMC1 do not mediate sigma-2 ligand-induced cell death.

Zeng C, Weng CC, Schneider ME Jr, Puentes L, Riad A, Xu K, Makvandi M, Jin L, Hawkins WG, Mach RH. Zeng C, et al. Cell Death Discov. 2019 Jan 28;5:58. doi: 10.1038/s41420-019-0141-2. eCollection 2019. Cell Death Discov. 2019. PMID: 30701090 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11 results

Search Page

Filters